
Immuneering Corp (IMRX) Stock Forecast & Price Target
Immuneering Corp (IMRX) Analyst Ratings
Bulls say
Immuneering Corp's progress in its clinical trials highlights significant advancements in overall survival (OS) and progression-free survival (PFS) rates, demonstrating marked improvements over existing standard of care (SoC) treatments for oncologic diseases. The improved safety profile of atebimetinib, along with its favorable tolerability compared to current therapies, strengthens its positioning in the market and enhances its potential to attract partnerships with pharmaceutical and biotechnology companies. Additionally, compelling case studies showcasing remarkable patient responses further bolster the outlook for the company's drug discovery programs and overall growth potential.
Bears say
The analysis highlights multiple regulatory risks associated with Immuneering Corp's product development that could lead to downward revisions in financial projections. The potential need for additional capital raises before achieving profitability raises concerns about share dilution for current shareholders. Furthermore, the ability of IMM-1-104 to significantly differentiate from existing MEKi profiles regarding activity or tolerability remains uncertain, which could further adversely impact financial estimates.
This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares